Deep Dive: Regulatory Status of Popular Compounded Peptides Holt Law The FDA just announced that they're taking steps to lift restrictions on 12 peptides including BPC 157 and TB 500 making them accessible through compounding pharmacies again. This is a HUGE step FDA Proposes Exclusion of Semaglutide, Tirzepatide, Liraglutide from 503B Bulks List FDA posted on the topic LinkedIn When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions Big news for peptides! In July, the FDA will meet to evaluate the most commonly used peptides for FDA authorized compounding.